FDC Ltd

- As of the current discussion, the management did not provide any specific guidance or plans regarding new fundraising through debt or equity. - They mentioned no comments on any upcoming fundraising activities or different amounts for the future. - If there is any development related to fundraising, the company stated they will surely update stakeholders. - The company is currently utilizing cash through shareholder rewards (buyback/dividend) and CAPEX investments (notably 70-80 crores for ophthalmic line expansion). - No explicit plans for raising debt or equity were indicated in the Q&A session on pages 5, 17, and 18.

- The company is investing about ₹70 to ₹80 crores in expanding and upgrading its ophthalmic manufacturing line at the Waluj plant. - This CAPEX is partly for replacement and upgradation purposes. - No specific guidance or numbers have been shared yet regarding returns or asset turns from this ophthalmic CAPEX; management may provide updates later. - Other than ophthalmic CAPEX, the company focuses on rewarding shareholders via buybacks or dividends using surplus cash (around ₹750 crores as of June). - There is no indicated major strategic investment or acquisition disclosed currently; the company is consolidating its core brands and expanding existing business lines. - Export business is an area where the company plans to continue investment to increase sales, ensuring risks are managed. - Promotion and marketing costs have increased, partly due to new divisions and launching focused marketing on top products, but no large new launches recently.

- Overall growth outlook is positive with an 11% revenue increase and 7.5% volume growth reported. - Top three products—Enerzal, Electral, and Zifi—show robust growth: Zifi up 11%, Electral 32%, and Enerzal 22% in recent quarters. - Plans are aggressive but cautious due to secondary market and external factors like COVID impact. - Growth expected to continue driven by focus on top 10 brands, expansion of product divisions, and new market penetrations. - Export market performing well; US exports increased by ₹7 crores year-over-year. - Marketing and sales efforts are being intensified with increased Medical Representative headcount. - Price hikes taken recently expected to positively impact margins and revenue. - Some quarter-to-quarter expense fluctuations due to promotional spend accounting; expect stabilization over the year. - Management optimistic about maintaining mid-teens growth rates going forward excluding one-off COVID impacts.

- The company plans to continue an aggressive growth strategy, focusing on execution and market trends to sustain momentum. - Growth drivers include key products like Enerzal, Electral, and Zifi, which showed volume growth of 22%, 32%, and 11% respectively in recent quarters. - The management is optimistic about outperforming the Indian Pharmaceutical Market (IPM) if market conditions remain stable. - Gross margins are expected to improve in upcoming quarters due to price hikes reflecting fully in inventory, though raw material and packaging costs remain a factor to watch. - Operating expenses, particularly sales and marketing costs, have increased but are expected to normalize or stabilize over the year. - Export business growth is targeted, especially in the US market, to contribute more significantly to overall revenues. - Overall revenue growth guidance is around 10-15% excluding one-off COVID-related items, with potential for sustained mid-to-high teens growth in the domestic business driven by multiple brands.

The provided transcript from the document "1000.pdf" does not contain any specific information or discussion related to the current or expected order book or pending orders of the company. The Q&A and management commentary largely focused on topics such as: - CAPEX on ophthalmic assets and related asset turns - Impact of online platforms on sales - Growth and volume contributions of key products like Enerzal, Electral, and Zifi - Marketing spend and promotional costs - Gross margin pressure due to inflation in raw materials and packaging - Export business and its margin profile - Use of cash including buyback and CAPEX plans No clear details or figures about order books or pending orders were mentioned on the analyzed pages. If you need insights on order book status, you might need to refer to other sections or documents.